broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K86118762-001-01-8 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.177471 | 0.080032 | -0.018003 | 0.758836 | 5,293.062397 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000966 |
BRD-K86972824-001-01-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.628049 | 0.075373 | -0.118031 | 0.868175 | 242.869284 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000966 |
BRD-K87737963-001-06-0 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.473616 | 0.333276 | 0.331171 | 0.764538 | 0.168127 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000966 |
BRD-K87782578-001-01-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | -0.783436 | 0.821157 | 0.597571 | 0.838221 | 9.302967 | 2.951556 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000966 |
BRD-K87909389-003-03-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.04953 | 1.271088 | 0.77204 | 0.574667 | 0.130299 | 0.141446 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000966 |
BRD-K88510285-001-17-8 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.082144 | 2.714276 | 0.666658 | 0.691434 | 0.09584 | 0.102391 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000966 |
BRD-K89014967-001-04-3 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 1.071836 | -0.301349 | 0.012807 | 1 | 0.005909 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000966 |
BRD-K92723993-001-17-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.646295 | 0.392162 | 0.067568 | 0.809836 | 0.047659 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000966 |
BRD-K95142244-001-01-5 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.437444 | 4.168004 | 0.592161 | 0.588123 | 0.008208 | 0.013514 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000966 |
BRD-K96123349-236-02-8 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.824675 | 0.196757 | -0.032486 | 0.889377 | 0.004191 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000966 |
BRD-K98572433-001-02-9 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.062007 | 0.66121 | 0.515842 | 0.650766 | 0.303507 | 0.370794 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000966 |
BRD-K99113996-001-02-0 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.166198 | 0.625058 | 0.852492 | 0.464195 | 0.016651 | 0.031782 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000966 |
BRD-K99616396-001-05-1 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.562192 | 0.076314 | -0.037518 | 0.855845 | 968.45891 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000966 |
BRD-K99749624-001-07-0 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 1.170435 | 0.063574 | -0.028794 | 1 | 0.033646 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000966 |
BRD-M97302542-001-04-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.77834 | 0.557763 | -0.025583 | 0.902246 | 0.150532 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000966 |
BRD-A25234499-001-19-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.893893 | -0.003933 | -0.002918 | 0.947381 | 0.001217 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000967 |
BRD-A70858459-001-01-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.740997 | -1.595935 | 0.234894 | 0.795235 | 1.343509 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000967 |
BRD-A74914197-001-02-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.769611 | 3.61779 | 0.440426 | 1 | 0.004925 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000967 |
BRD-K02113016-001-19-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.001618 | -0.017716 | -0.013182 | 1 | 46.134423 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000967 |
BRD-K02130563-001-11-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.284988 | 5.159604 | 0.324668 | 0.688093 | 0.145028 | 0.170799 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000967 |
BRD-K03406345-001-21-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.225465 | 0.191324 | 0.052782 | 1 | 0.31492 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000967 |
BRD-K03449891-001-08-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 51.444721 | 2.068682 | 0.379019 | 1 | 65.918374 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000967 |
BRD-K03765900-001-01-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.298303 | 1.561441 | 0.65326 | 0.918361 | 3.647374 | 6.523561 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000967 |
BRD-K05804044-001-18-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 3.823596 | 1.963735 | -0.020418 | 1 | 29.545967 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000967 |
BRD-K06814349-304-02-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.179276 | -0.064131 | -0.043414 | 1 | 34.385789 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000967 |
BRD-K08109215-001-06-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.115754 | 0.016636 | -0.009258 | 1 | 0.008 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000967 |
BRD-K08542803-001-02-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.096684 | 1.33695 | 0.676728 | 0.620937 | 0.170847 | 0.200637 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000967 |
BRD-K08547377-001-04-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.094674 | -0.113835 | -0.085122 | 1 | 329.228998 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000967 |
BRD-K08703257-001-13-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.754126 | 0.357318 | -0.068419 | 0.88125 | 0.098914 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000967 |
BRD-K08799216-001-05-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 2.768542 | 0.510381 | -0.30326 | 1 | 10.474607 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000967 |
BRD-K09951645-001-11-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.654121 | -0.031526 | -0.075532 | 0.813569 | 11.234923 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000967 |
BRD-K11267252-001-05-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.818068 | -0.610749 | 0.068584 | 0.944956 | 0.008761 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000967 |
BRD-K11630072-001-13-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.536102 | -1.03354 | 0.245822 | 0.931398 | 0.001998 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000967 |
BRD-K12184916-001-19-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.41577 | 0.040628 | -0.012942 | 1 | 0.142371 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000967 |
BRD-K13049116-001-04-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 3.067132 | 0.981843 | 0.663249 | 1 | 2.307681 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000967 |
BRD-K13390322-001-06-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.119666 | 0.946856 | 0.493016 | 0.68292 | 0.314586 | 0.419964 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000967 |
BRD-K13514097-001-04-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 2.102375 | -0.081109 | 0.05273 | 1 | 0.000063 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000967 |
BRD-K13662825-001-07-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.257427 | 0.462692 | 0.621585 | 0.599357 | 0.012161 | 0.058061 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000967 |
BRD-K14109347-001-03-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 7.495159 | 1.541715 | 0.271733 | 1 | 24.565668 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000967 |
BRD-K15179879-001-03-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.189511 | 4.537196 | 0.7037 | 0.344268 | 0.003891 | 0.004322 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000967 |
BRD-K15600710-066-05-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.322611 | 0.180524 | -0.053829 | 1 | 0.009077 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000967 |
BRD-K16730910-001-10-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.230741 | 2.795016 | 0.094607 | 1 | 1.270984 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000967 |
BRD-K17555800-003-02-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.157804 | -0.277989 | -0.124332 | 1 | 0.013128 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000967 |
BRD-K17610631-001-03-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.215691 | 1.580335 | 0.736623 | 0.597101 | 0.066229 | 0.094667 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000967 |
BRD-K17894950-001-14-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.891046 | 0.607694 | -0.01375 | 0.982006 | 4.34062 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000967 |
BRD-K18961567-001-01-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.949499 | -0.976945 | -0.006496 | 0.972816 | 0.11402 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000967 |
BRD-K19540840-001-09-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.939277 | -5.483649 | -0.038379 | 0.969652 | 0.077933 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000967 |
BRD-K19687926-001-04-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.948144 | -0.78189 | -0.129421 | 0.976238 | 0.051091 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000967 |
BRD-K19796430-001-05-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.477465 | -0.113929 | -0.01608 | 1 | 0.102202 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000967 |
BRD-K22064724-001-01-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.095487 | 1.161655 | 0.339267 | 0.628022 | 0.186158 | 0.223414 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000967 |
BRD-K22822991-001-02-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.971544 | 0.369209 | 0.006748 | 0.977634 | 0.00106 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000967 |
BRD-K23228615-001-02-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.864579 | -0.457868 | -0.097692 | 0.965669 | 0.00329 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000967 |
BRD-K23984367-001-07-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.999969 | -0.354743 | -0.075255 | 0.999981 | 0.420618 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000967 |
BRD-K26026438-001-01-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.820343 | 6.958095 | 0.232141 | 0.882973 | 0.017972 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000967 |
BRD-K26657438-001-15-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.825376 | 1.116634 | -0.01492 | 0.863037 | 0.004517 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000967 |
BRD-K28822270-001-03-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.897147 | -0.44474 | -0.02836 | 0.991095 | 0.000113 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000967 |
BRD-K29905972-001-06-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 2.176473 | 2.409413 | 0.534232 | 1 | 3.754727 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000967 |
BRD-K30577245-001-05-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.239061 | -1.129975 | 0.075262 | 1 | 0.056642 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000967 |
BRD-K31698212-001-02-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.116082 | 0.06857 | -0.027779 | 1 | 0.000028 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000967 |
BRD-K31928526-001-02-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.45818 | 0.708256 | 0.424568 | 1 | 0.245342 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000967 |
BRD-K33610132-001-02-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.120657 | -0.238753 | -0.277059 | 1 | 5.028352 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000967 |
BRD-K33622447-066-01-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.53995 | 1.337065 | 0.369077 | 0.92072 | 2.043599 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000967 |
BRD-K35520305-001-16-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.57164 | 19.654792 | 0.57047 | 1 | 0.809879 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000967 |
BRD-K36627727-001-05-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.197089 | -0.777283 | -0.055201 | 1 | 0.075707 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000967 |
BRD-K36788280-001-01-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.808295 | -0.076324 | -0.002619 | 0.862715 | 16,369.86685 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000967 |
BRD-K37379014-001-02-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.751918 | -1.092238 | 0.141771 | 0.879028 | 0.00108 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000967 |
BRD-K38332599-001-01-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 2.976965 | 1.144852 | 0.673242 | 1 | 0.838435 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000967 |
BRD-K38527262-300-01-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.999345 | 0.70092 | -0.018632 | 0.999998 | 2,095.281274 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000967 |
BRD-K38852836-001-02-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.839076 | 1.330086 | 0.016856 | 0.959735 | 0.227468 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000967 |
BRD-K39974922-001-04-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.00235 | -0.218342 | -0.076151 | 1 | 32.869698 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000967 |
BRD-K41859756-001-06-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.017387 | 0.234817 | -0.031469 | 1 | 0.000106 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000967 |
BRD-K42495768-001-01-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.573704 | 0.290323 | 0.203528 | 0.854966 | 1.086671 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000967 |
BRD-K42805893-001-04-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.184542 | 1.036604 | -0.005165 | 1 | 11,722.254947 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000967 |
BRD-K42828737-001-03-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.116745 | -0.002433 | 0.000098 | 1 | 1,472,318,885,051,069,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000967 |
BRD-K42898655-001-01-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.383077 | 5.556515 | 0.542228 | 1 | 0.000343 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000967 |
BRD-K43389675-001-02-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.786495 | 2.082171 | -0.082964 | 1 | 0.021856 | null | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000967 |
BRD-K44227013-001-06-4 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.063233 | 0.256011 | -0.003459 | 1 | 0.976056 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000967 |
BRD-K44408410-001-17-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.750153 | -0.888383 | 0.143292 | 0.952228 | 0.003071 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000967 |
BRD-K44827188-001-06-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.637461 | 5.09003 | 0.048241 | 0.902354 | 0.732536 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000967 |
BRD-K46386702-001-02-1 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.779638 | -5.533314 | 0.269442 | 0.898575 | 0.053113 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000967 |
BRD-K49328571-001-15-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.50907 | 1.223351 | 0.465178 | 1 | 0.010844 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000967 |
BRD-K49350383-001-14-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 2.637831 | 1.388942 | 0.796985 | 1 | 1.362993 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000967 |
BRD-K50010139-001-01-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.060939 | -0.004961 | -0.040973 | 1 | 1,963,778,699,762,502,500,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000967 |
BRD-K50168500-001-07-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.808646 | -0.119229 | -0.191214 | 0.887439 | 1.688384 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000967 |
BRD-K51313569-001-07-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.19733 | 0.130035 | -0.067906 | 1 | 0.030118 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000967 |
BRD-K51791723-003-01-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.156627 | 0.94408 | 0.707359 | 0.708937 | 0.366607 | 0.54585 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000967 |
BRD-K51967704-001-03-6 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.372469 | 0.616249 | 0.076932 | 1 | 0.937803 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000967 |
BRD-K52313696-001-12-3 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.699765 | 0.513293 | 0.373413 | 1 | 0.937889 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000967 |
BRD-K53414658-001-08-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.919082 | -0.528509 | -0.112516 | 0.943312 | 0.820842 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000967 |
BRD-K53972329-001-07-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.765077 | -1.165848 | 0.173059 | 0.925502 | 0.01293 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000967 |
BRD-K54256913-001-08-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | -0.397899 | 2.88635 | 0.361373 | 0.962787 | 9.651305 | 7.879453 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000967 |
BRD-K54955827-001-02-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.162616 | -0.090252 | -0.033123 | 1 | 207.204721 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000967 |
BRD-K54997624-001-06-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.829166 | -4.853066 | 0.045931 | 0.939702 | 0.018747 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000967 |
BRD-K55187425-236-05-2 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.513171 | 0.899779 | 0.13014 | 0.65774 | 0.01001 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000967 |
BRD-K56981171-001-02-8 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.828668 | 1.176069 | 0.040017 | 0.879416 | 0.010496 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000967 |
BRD-K57080016-001-15-9 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 2.040621 | 0.978492 | 0.75656 | 1 | 0.137079 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000967 |
BRD-K57169635-001-04-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | -0.132863 | 5.120672 | 0.506987 | 0.983681 | 9.912751 | 9.467015 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000967 |
BRD-K58435339-001-03-0 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 1.007883 | -0.321874 | -0.214242 | 1 | 0.267752 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000967 |
BRD-K58529924-001-01-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.688523 | -0.6748 | 0.02865 | 0.925959 | 0.00462 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000967 |
BRD-K58550667-001-08-7 | ACH-000967 | SNUC2A_LARGE_INTESTINE | MTS010 | 1 | 0.221841 | 9.635365 | 0.49716 | 0.838391 | 0.083275 | 0.0885 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000967 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.